POLIDOCANOL - Generic Drug Details

What are the generic drug sources for polidocanol and what is the scope of freedom to operate?

Polidocanol is the generic ingredient in two branded drugs marketed by Chemisch Fbrk Krsslr and Provensis, and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Polidocanol has thirty-one patent family members in eighteen countries.

Two suppliers are listed for this compound.

Summary for POLIDOCANOL

International Patents:	31
US Patents:	2
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	30
What excipients (inactive ingredients) are in POLIDOCANOL?	POLIDOCANOL excipients list
DailyMed Link:	POLIDOCANOL at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for POLIDOCANOL

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for POLIDOCANOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital Universitario Pedro Ernesto	NA
Sohag University	NA
Assiut University	NA

See all POLIDOCANOL clinical trials

Pharmacology for POLIDOCANOL

Drug Class	Sclerosing Agent
Mechanism of Action	Sclerosing Activity
Physiological Effect	Vascular Sclerosing Activity

Anatomical Therapeutic Chemical (ATC) Classes for POLIDOCANOL

C05BB	Sclerosing agents for local injection
C05B	ANTIVARICOSE THERAPY
C05	VASOPROTECTIVES
C	Cardiovascular system

US Patents and Regulatory Information for POLIDOCANOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemisch Fbrk Krsslr	ASCLERA	polidocanol	SOLUTION;INTRAVENOUS	021201-001	Mar 30, 2010		RX	Yes	No
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098-001	Nov 25, 2013		RX	Yes	Yes			Y
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098-001	Nov 25, 2013		RX	Yes	Yes			Y

Expired US Patents for POLIDOCANOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098-001	Nov 25, 2013
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098-001	Nov 25, 2013
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098-001	Nov 25, 2013

International Patents for POLIDOCANOL

Country	Patent Number	Title	Estimated Expiration
Japan	5107445
United Kingdom	0321210
Denmark	1945533

POLIDOCANOL Market Analysis and Financial Projection

Last updated: February 14, 2026

What are the current market dynamics for polidocanol?

Polidocanol is a sclerosing agent used primarily in the treatment of varicose veins, spider veins, and certain vascular anomalies. The drug is marketed under various brand names including Asclera and Lauromacrogols, with manufacturing concentrated primarily in Europe and North America. The global market for polidocanol is influenced by several factors:

• Growing prevalence of venous disorders: Increasing incidence of chronic venous diseases, driven by aging populations and sedentary lifestyles, expands the patient base.
• Preference for minimally invasive procedures: Medical shift towards outpatient, minimally invasive treatments boosts demand for sclerosing agents.
• Regulatory approval and market access: Various regulatory agencies, including the FDA and EMA, have approved polidocanol formulations, facilitating market penetration.
• Competition from alternative therapies: Foam sclerotherapy using polidocanol faces competition from laser therapy, radiofrequency ablation, and other sclerosing agents like sodium tetradecyl sulfate.
• Market fragmentation: The space features a mix of global and regional players, with companies like Snowmass, Merz Pharma, and local generic manufacturers.

In 2022, the global vascular sclerotherapy market was valued at approximately USD 610 million, with polidocanol representing a significant share due to its favorable safety profile and efficacy.

How is the financial trajectory of polidocanol expected to evolve?

The financial outlook for polidocanol indicates steady growth. Key projections include:

• Compound Annual Growth Rate (CAGR): Estimated at around 6-8% for the vascular sclerotherapy market between 2023 and 2028[1].
• Revenue estimates: Global revenues for polidocanol products are projected to reach USD 850-900 million by 2028[2].
• Market share dynamics: The segment's growth is driven mainly by North America and Europe, where minimally invasive vein treatments are well-established and expanding into emerging markets.
• Pricing trends: Prices for polidocanol formulations have remained relatively stable with slight increases in regions with high demand, affected by manufacturing costs and regulatory compliance expenses.
• R&D investments: Increased investment in novel formulations, such as foam and nano-drug delivery systems, may influence future costs and revenues.

Major pharmaceutical companies have been investing in expanding indications, which could diversify revenue streams. For example, Merz Pharma launched Asclera in the U.S., with revenues reaching approximately USD 50 million annually by 2022[3].

What are the key factors influencing market growth and revenue?

Factors impacting revenue growth for polidocanol include:

• Regulatory approvals: Expanding indications for medical conditions like hemorrhoids and lymphatic malformations could unlock new markets.
• Demographic shifts: Aging populations increase demand for vascular treatments.
• Technological advances: Improvements in foam technology and imaging-guided procedures make treatments more effective, favorably affecting market value.
• Market competition: Continued presence of alternative treatments puts pressure on pricing and market share.
• Geographical expansion: Entry into Asian and Latin American markets presents growth opportunities, enabled by regulatory standardization and healthcare infrastructure improvements.

How do competitive and regulatory landscapes impact financial forecasts?

The competitive landscape features several regional and generic manufacturers, impacting pricing strategies and profit margins. Patent expirations in key markets could lead to increased generic competition, pressuring prices.

Regulatory landscapes vary by region:

• United States: FDA approval processes for new indications or formulations can extend time-to-market, delaying revenue growth.
• Europe: EMA approvals facilitate easier regional expansion but require compliance with stringent safety standards which can increase initial costs.
• Emerging markets: Regulatory pathways are evolving; approval processes often faster but associated with less established safety monitoring mechanisms.

Investment into clinical trials for expanded indications influences costs but can generate additional revenue streams if successful.

What is the outlook on potential market entry and barriers?

Entry barriers include regulatory approval costs, establishing manufacturing capacity, and gaining acceptance among clinicians. Patent landscapes can provide temporary market exclusivity, but expiration timelines are critical for forecasting generic competition and price erosion.

The growing adoption of foam sclerotherapy enhances the attractiveness of polidocanol, with clinical advantages over liquid formulations. However, competition from laser and radiofrequency modalities remains a challenge.

Key Takeaways

• Market value is projected to grow at 6-8% CAGR from 2023-2028.
• Revenues are expected to approach USD 900 million globally, with North America and Europe leading.
• Demographic trends and technological improvements are key growth drivers.
• Competition from alternative therapies and generics pose risks to pricing and market share.
• Regulatory pathways and patent expiration timeline will significantly influence future revenue potential.

FAQs

1. Which regions present the highest growth potential for polidocanol?
Emerging markets in Asia and Latin America are expected to grow rapidly, driven by increasing healthcare infrastructure and rising awareness of minimally invasive treatments.

2. What are main clinical advantages of polidocanol over other sclerosing agents?
Polidocanol has a favorable safety profile, causes less pain and hypersensitivity reactions, and can be used as foam, offering better lesion obliteration.

3. How does patent expiration impact the polidocanol market?
Patent expirations typically lead to the entry of generics, which lowers prices and market share for branded formulations, potentially reducing revenues.

4. Are new indications impacting revenue projections?
Yes. Investigations into polidocanol's use for hemorrhoids and lymphatic malformations could expand the addressable market if approved, increasing revenue streams.

5. What role does technological innovation play in future market growth?
Advances in foam technology, imaging guidance, and delivery systems improve treatment outcomes, which can expand patient acceptance and market size.

---

Sources:

1. Market Research Future. "Vascular Sclerotherapy Market Forecast 2023-2028."
2. Smithers Apex. "Global Sclerotherapy Market Report 2022."
3. Merz Pharma. Annual Report 2022.